Cargando…
Systemic Therapy of Non-Resectable Metastatic Melanoma
In advanced metastatic melanoma (non-resectable stage III/IV), the prognosis still remains poor, with median survival times between six and twelve months. Systemic therapeutic approaches for metastatic melanoma include chemotherapy, immunotherapy, immunochemotherapy, small molecules and targeted the...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3835112/ https://www.ncbi.nlm.nih.gov/pubmed/24281101 http://dx.doi.org/10.3390/cancers2020955 |
_version_ | 1782292102957236224 |
---|---|
author | Orouji, Azadeh Goerdt, Sergij Utikal, Jochen |
author_facet | Orouji, Azadeh Goerdt, Sergij Utikal, Jochen |
author_sort | Orouji, Azadeh |
collection | PubMed |
description | In advanced metastatic melanoma (non-resectable stage III/IV), the prognosis still remains poor, with median survival times between six and twelve months. Systemic therapeutic approaches for metastatic melanoma include chemotherapy, immunotherapy, immunochemotherapy, small molecules and targeted therapy. In this review, we will focus on the various treatment modalities as well as new agents used for targeted therapy. |
format | Online Article Text |
id | pubmed-3835112 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-38351122013-11-21 Systemic Therapy of Non-Resectable Metastatic Melanoma Orouji, Azadeh Goerdt, Sergij Utikal, Jochen Cancers (Basel) Review In advanced metastatic melanoma (non-resectable stage III/IV), the prognosis still remains poor, with median survival times between six and twelve months. Systemic therapeutic approaches for metastatic melanoma include chemotherapy, immunotherapy, immunochemotherapy, small molecules and targeted therapy. In this review, we will focus on the various treatment modalities as well as new agents used for targeted therapy. MDPI 2010-05-26 /pmc/articles/PMC3835112/ /pubmed/24281101 http://dx.doi.org/10.3390/cancers2020955 Text en © 2010 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Review Orouji, Azadeh Goerdt, Sergij Utikal, Jochen Systemic Therapy of Non-Resectable Metastatic Melanoma |
title | Systemic Therapy of Non-Resectable Metastatic Melanoma |
title_full | Systemic Therapy of Non-Resectable Metastatic Melanoma |
title_fullStr | Systemic Therapy of Non-Resectable Metastatic Melanoma |
title_full_unstemmed | Systemic Therapy of Non-Resectable Metastatic Melanoma |
title_short | Systemic Therapy of Non-Resectable Metastatic Melanoma |
title_sort | systemic therapy of non-resectable metastatic melanoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3835112/ https://www.ncbi.nlm.nih.gov/pubmed/24281101 http://dx.doi.org/10.3390/cancers2020955 |
work_keys_str_mv | AT oroujiazadeh systemictherapyofnonresectablemetastaticmelanoma AT goerdtsergij systemictherapyofnonresectablemetastaticmelanoma AT utikaljochen systemictherapyofnonresectablemetastaticmelanoma |